GlassScriptPhysician profile
Paul A Strodtbeck
NPI 1699805275
$3,390.49
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $414 · 2021: $541 · 2022: $933 · 2023: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $529.52 | 2019-2023 | Farxiga, Fasenra |
| Janssen Pharmaceuticals, INC | $356.94 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $278.66 | 2019-2021 | |
| Amgen INC. | $235.07 | 2019-2023 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $217.09 | 2019-2023 | |
| Pfizer INC. | $197.97 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $149.06 | 2022 | |
| Abbvie INC. | $146.68 | 2019-2022 | |
| Novo Nordisk INC | $145.89 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.14 | 2021-2023 | |
| Glaxosmithkline, LLC. | $118.15 | 2019-2023 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $103.94 | 2019-2023 | Verquvo, Belsomra, Vaxneuvance |
| Allergan, INC. | $103.84 | 2019-2020 | |
| Radius Health, INC. | $61.62 | 2019-2020 | |
| Eisai INC. | $60.81 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $60.35 | 2022-2023 | Jynarque |
| Amarin Pharma, INC. | $54.72 | 2019-2021 | |
| Boston Scientific Corporation | $53.27 | 2022 | |
| Sanofi Pasteur INC. | $46.21 | 2019-2020 | |
| Almatica Pharma LLC | $32.40 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.22 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $26.65 | 2023 | Crysvita |
| Lilly USA, LLC | $25.64 | 2022 | |
| Kyowa Kirin, INC. | $25.47 | 2023 | |
| Lucid Diagnostics INC. | $23.73 | 2022 | |
| Exact Sciences Corporation | $22.67 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.15 | 2021 | |
| Bausch Health US, LLC | $18.18 | 2019 | |
| Shield Therapeutics INC | $17.42 | 2022 | |
| Qiagen, LLC | $17.36 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.98 | 2019 | |
| Ibsa Pharma INC. | $15.49 | 2022 | |
| Edwards Lifesciences Corporation | $15.47 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Optos, INC. | $14.31 | 2021 | |
| Itamar Medical INC | $8.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Strodtbeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.